Feasibility of using low frequency clinical ultrasound transducer for activation of in Acoustic Cluster Therapy
The PC3 model has proved reliable and productive for assessing ACT efficacy. It has successfully produced significant results required for proof of principle and optimisation studies which has led to several publications. The model has been successfully used in several studies and we have sufficient historical data to adequately power new studies with the use of Abraxane as the chemotherapeutic. The most recent study has demonstrated that a custom designed clinical transducer with low frequency at 900kHz to drive therapy bioeffects is sub optimal compared to 500kHz pulses produced by a single element transducer.
This has led to the specification development, design and construction of a new prototype clinical scanner probe to operate in the optimal frequency range. It is not possible to match the single element transducer field output exactly with the clinical probe prototype.
It is thus proposed to use this model to validate the therapeutic efficacy of the new clinical scanner transducer which may be used in the first in-man clinical studies if successful.
The PC3 model has proved stable, and we plan to only include a small cohort of non-treatment controls to show the consistency of tumour growth, and to compare the new probe results to historical controls at the other ultrasound settings to significantly reduce animal numbers in compliance with the three R’s.
Our previous experience performing these types of experiments has shown us that the animals handle this type of tumor and treatments very well. In total 60 animals are applied for.
This has led to the specification development, design and construction of a new prototype clinical scanner probe to operate in the optimal frequency range. It is not possible to match the single element transducer field output exactly with the clinical probe prototype.
It is thus proposed to use this model to validate the therapeutic efficacy of the new clinical scanner transducer which may be used in the first in-man clinical studies if successful.
The PC3 model has proved stable, and we plan to only include a small cohort of non-treatment controls to show the consistency of tumour growth, and to compare the new probe results to historical controls at the other ultrasound settings to significantly reduce animal numbers in compliance with the three R’s.
Our previous experience performing these types of experiments has shown us that the animals handle this type of tumor and treatments very well. In total 60 animals are applied for.